Loading organizations...
Cradle Genomics is a San Diego, California-based biotechnology company that develops non-invasive prenatal testing and comprehensive fetal genetic analysis solutions. The organization focuses on advancing early-stage prenatal diagnostics through novel cellular techniques, specifically by isolating trophoblast cells to facilitate genetic screening and at-home sample collection. The firm's methodology provides an alternative to traditional clinical procedures by allowing pregnant women to utilize remote testing kits to gather essential reproductive health data. To support its clinical development and operational scale, the enterprise successfully secured $17 million in Series A funding from a syndicate of specialized life sciences backers. This financing round was co-led by prominent industry investors Illumina Ventures and Section 32 to further advance their proprietary diagnostic platforms. Cradle Genomics was founded in 2021 by the executive team of Randy Armant, Sascha Drewlo, Richard Shippy, and Tristan Orpin.
Cradle Genomics has raised $17.1M across 1 funding round.
Cradle Genomics has raised $17.1M in total across 1 funding round.
Cradle Genomics has raised $17.1M in total across 1 funding round.
Cradle Genomics's investors include Nicholas J. Naclerio, Section 32, Alexandria Venture Investments, Axon Ventures, Listwin Ventures, Sea Lane Ventures.
Cradle Genomics has raised $17.1M across 1 funding round. Most recently, it raised $17.1M Series A in July 2019.
| Date | Round | Lead Investors | Other Investors | Status |
|---|---|---|---|---|
| Jul 16, 2019 | $17.1M Series A | Nicholas J. Naclerio, Section 32 | Alexandria Venture Investments, Axon Ventures, Listwin Ventures, SEA Lane Ventures | Announced |
